4,171 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,171 shares of the medical device company’s stock, valued at approximately $280,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Crewe Advisors LLC acquired a new position in DexCom in the 1st quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the 2nd quarter valued at approximately $25,000. Sachetta LLC increased its position in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. DT Investment Partners LLC increased its position in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the period. Finally, Riverview Trust Co increased its position in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Canaccord Genuity Group reiterated a “buy” rating and set a $145.00 price objective on shares of DexCom in a research report on Tuesday, July 23rd. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a research report on Friday, October 25th. Stifel Nicolaus increased their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, August 23rd. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Stock Down 0.9 %

DexCom stock opened at $69.70 on Tuesday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The firm has a market capitalization of $27.22 billion, a price-to-earnings ratio of 41.74, a price-to-earnings-growth ratio of 2.16 and a beta of 1.17. The firm’s fifty day moving average price is $69.77 and its two-hundred day moving average price is $94.92. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares in the company, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.